CVA Family Office’s Amicus Therapeutics FOLD Stock Holding History

CVA Family Office’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-43	Closed	-$459	–	1309
2024 Q3	$459	Buy	+43	New	+$468	﹤0.01%	1236

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CVA Family Office's FOLD Position: Q4 2024 in Review

CVA Family Office sold out of Amicus Therapeutics (FOLD) in Q4 2024, closing a stake of 43 shares — an estimated $459 sold.

CVA Family Office first reported a position in FOLD in Q3 2024 and held it in 1 quarter. The position peaked at $459 in Q3 2024. 290 funds tracked by Wall St. Rank hold FOLD as of Q4 2024.

CVA Family Office reported no remaining Amicus Therapeutics position as of Q4 2024 after selling out during the quarter.
CVA Family Office sold 43 Amicus Therapeutics shares in Q4 2024, an estimated $459.
CVA Family Office first reported a position in Amicus Therapeutics in Q3 2024 and held it in 1 quarter.
CVA Family Office's Amicus Therapeutics position peaked at $459 in Q3 2024.
290 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2024.

Based on CVA Family Office's 13F filing for Q4 2024, filed 7 Jan 2025.